Evaluation of an Intervention on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults
Launched by UNIVERSITY OF CHICAGO · Sep 12, 2005
Trial Information
Current as of May 27, 2025
Terminated
Keywords
ClinConnect Summary
--Background--
The management of HIV has changed dramatically since the introduction of highly active antiretroviral therapy (HAART). HAART consists of a drug regimen that targets the virus at various points in its life cycle and is thus more effective than monotherapy. The drugs that comprise this regimen usually belong to different classes of antiretrovirals.
HAART regimens can be complex and difficult to tolerate. They usually consist of multiple pills that have to be taken two to three times a day and may also need to be taken with food, on an empty stomach or with plenty of fluids (d...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patient must have HIV to participate
- • patient must be at least 18 years of age or older
- • must have been on HAART for six weeks
- • must have a working telephone number
- Exclusion Criteria:
- • patient is HIV negative
- • patient is younger than 18 years of age
- • patient has been on HAART for less than 6 weeks
- • if patient does not have a working telephone number, he/she cannot participate in the study
About University Of Chicago
The University of Chicago is a prestigious research institution renowned for its commitment to advancing medical science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, the University actively engages in cutting-edge research across various therapeutic areas. Its dedicated team of experienced investigators and state-of-the-art facilities enable the University of Chicago to conduct rigorous clinical studies aimed at improving patient outcomes and translating scientific discoveries into tangible healthcare solutions. The institution prioritizes ethical standards and patient safety, ensuring that all trials adhere to the highest regulatory guidelines and best practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Jean-Luc Benoit, MD
Principal Investigator
University of Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials